Pharmafile Logo
Pharmafocus logo
Advanced Search

Oncology

Showing 15 posts of 168 posts found.

Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment

March 26, 2024
Research and Development Cancer, Curve Therapeutics, HIF inhibition, Oncology, oncology

Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research in the Journal of the …

News

AstraZeneca to acquire Fusion for approximately $2bn

March 19, 2024
Business Services AstraZeneca, Fusion Pharmaceuticals, Oncology, acquisition, radioconjugates

AstraZeneca has announced that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals for an approximate $2bn. This …

News

GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

March 18, 2024
Research and Development GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health

GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) …

News

Merck shares results for Keytruda in cervical cancer treatment

March 18, 2024
Research and Development Merck, Oncology, cervical cancer, keytruda, women's health

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …

News

Bayer and Aignostics to collaborate for AI oncology research

March 14, 2024
Research and Development AI, Bayer, Oncology, research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several artificial intelligence (AI)-powered approaches for …

News

Merck completes acquisition of Harpoon Therapeutics for $650m

March 12, 2024
Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …

News

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

March 11, 2024
Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …

News

BeiGene’s Brukinsa gains FDA accelerated approval for follicular lymphoma treatment

March 8, 2024
Medical Communications BeiGene, Brukinsa, FDA, Oncology, follicular lymphoma

BeiGene has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib) for the …

News

GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma

March 7, 2024
Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma

GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …

News

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

March 5, 2024
Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …

News

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

March 4, 2024
Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant

Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …

News
louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

March 4, 2024
Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …

News

Cardiff Oncology doses first patient in colorectal cancer trial

March 1, 2024
Research and Development Cardiff Oncology, Oncology, clinical trial, colorectal cancer

Cardiff Oncology has announced that it has dosed the first patient in its randomised first-line phase 2 trial, CRDF-004, for …

News

Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial

March 1, 2024
Medical Communications Oncology, Viracta Therapeutics, lymphoma

Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …

News

AbbVie and Tentarix collaborate on oncology and immunology treatments

February 23, 2024
Research and Development AbbVie, Oncology, collaboration, immunology

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024